These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 20558470)

  • 1. Support for higher ciprofloxacin AUC 24/MIC targets in treating Enterobacteriaceae bloodstream infection.
    Zelenitsky SA; Ariano RE
    J Antimicrob Chemother; 2010 Aug; 65(8):1725-32. PubMed ID: 20558470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
    Montgomery MJ; Beringer PM; Aminimanizani A; Louie SG; Shapiro BJ; Jelliffe R; Gill MA
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints.
    Stass H; Dalhoff A
    Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data.
    Burgess DS; Hall RG
    Clin Ther; 2007 Jul; 29(7):1421-7. PubMed ID: 17825693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing ciprofloxacin dosing in intensive care unit patients through the use of population pharmacokinetic-pharmacodynamic analysis and Monte Carlo simulations.
    Khachman D; Conil JM; Georges B; Saivin S; Houin G; Toutain PL; Laffont CM
    J Antimicrob Chemother; 2011 Aug; 66(8):1798-809. PubMed ID: 21653603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study.
    van Zanten AR; Polderman KH; van Geijlswijk IM; van der Meer GY; Schouten MA; Girbes AR
    J Crit Care; 2008 Sep; 23(3):422-30. PubMed ID: 18725050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study of pharmacokinetics/ pharmacodynamics of ciprofloxacin between 400 mg intravenously every 8 h and 400 mg intravenously every 12 h in patients with gram negative bacilli bacteremia.
    Saengsuwan P; Jaruratanasirikul S; Jullangkoon M; Aeinlang N
    J Med Assoc Thai; 2010 Jul; 93(7):784-8. PubMed ID: 20649056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of a clinically derived exposure-response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints.
    Ambrose PG; Meagher AK; Passarell JA; Van Wart SA; Cirincione BB; Rubino CM; Korth-Bradley JM; Babinchak T; Ellis-Grosse E
    Diagn Microbiol Infect Dis; 2009 Jan; 63(1):38-42. PubMed ID: 19073300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP).
    Noreddin AM; Marras TK; Sanders K; Chan CK; Hoban DJ; Zhanel GG
    Int J Antimicrob Agents; 2004 Nov; 24(5):479-84. PubMed ID: 15519481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
    Burgess DS; Frei CR
    J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of garenoxacin tested against a worldwide collection of ciprofloxacin-susceptible and ciprofloxacin-resistant Enterobacteriaceae strains (1999-2004).
    Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2007 May; 58(1):27-32. PubMed ID: 17383140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic target attainment of seven antimicrobials against Gram-negative bacteria collected from China in 2003 and 2004.
    Wang H; Zhang B; Ni Y; Kuti JL; Chen B; Chen M; Nicolau DP
    Int J Antimicrob Agents; 2007 Nov; 30(5):452-7. PubMed ID: 17646088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model.
    Firsov AA; Alferova IV; Smirnova MV; Lubenko IY; Portnoy YA; Zinner SH
    Int J Antimicrob Agents; 2005 May; 25(5):409-13. PubMed ID: 15848296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model.
    Zinner SH; Vostrov SN; Alferova IV; Lubenko IY; Portnoy YA; Firsov AA
    Int J Antimicrob Agents; 2004 Aug; 24(2):173-7. PubMed ID: 15288317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States.
    Koomanachai P; Bulik CC; Kuti JL; Nicolau DP
    Clin Ther; 2010 Apr; 32(4):766-79. PubMed ID: 20435246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simulation of antibiotic pharmacodynamic exposure for the empiric treatment of nosocomial bloodstream infections: a report from the OPTAMA program.
    Maglio D; Kuti JL; Nicolau DP
    Clin Ther; 2005 Jul; 27(7):1032-42. PubMed ID: 16154482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia.
    Kim A; Kuti JL; Nicolau DP
    Clin Ther; 2009 Nov; 31(11):2765-78. PubMed ID: 20110018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reevaluation of Enterobacteriaceae MIC/disk diffusion zone diameter regression scattergrams for 9 beta-lactams: adjustments of breakpoints for strains producing extended spectrum beta-lactamases.
    Jones RN; Craig WA; Ambrose PG; Dudley MN; Pottumarthy S
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):235-46. PubMed ID: 16105568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe.
    Masterton RG; Kuti JL; Turner PJ; Nicolau DP
    J Antimicrob Chemother; 2005 Jan; 55(1):71-7. PubMed ID: 15574471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002.
    Kuti JL; Nightingale CH; Nicolau DP
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2464-70. PubMed ID: 15215095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.